At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 177 enrolled
Drug / intervention
Belantamab mafodotindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Parallel, Open-label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Various Dosing Regimens of Single-agent Belantamab Mafodotin (GSK2857916) in Participants With Relapsed or Refractory Multiple Myeloma (DREAMM-14)
In Brief
A Phase 2 clinical trial evaluating Belantamab mafodotin for Multiple Myeloma. Completed, enrolled 177 participants across 77 sites in 18 countries.
Detailed Summary
This study aims to evaluate alternative dosing regimens of single-agent belantamab mafodotin in participants with relapsed or refractory multiple myeloma (RRMM) to determine if an improved overall benefit/risk profile can be achieved by modifying the belantamab mafodotin dose, schedule, or both.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesArgentina, Australia, Brazil, Canada, France, Germany, Greece, Ireland, Italy, Mexico, Poland, South Korea, Spain, Switzerland, Taiwan, Thailand, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedOct 2021
Enrollment StartMar 2022
Primary CompletionAug 2024
Study CompletionFeb 2026
TodayJul 2026
First PostedOct 1, 2021
Enrollment StartMar 3, 2022
Primary CompletionAug 19, 2024
Study CompletionFeb 10, 2026
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 4.8 years ago
Interventions
Belantamab mafodotindrug
Belantamab mafodotin will be administered.